论文部分内容阅读
目的铂类是肺癌化疗的基础药物,而切除交叉互补修复酶1表达水平与铂类耐药和预后有关,本研究分析可手术非小细胞肺癌的切除交叉互补修复酶1表达与术后生存期的关系,探讨它们与患者预后及与铂类耐药的相关性。方法收集2005年12月-2009年1月随访的95例Ⅱ～Ⅲ期非小细胞肺癌患者,均进行根治性手术切除及术后以铂类为基础的化疗。免疫组化法检测手术标本的切除交叉互补修复酶1表达,并进行统计分析。结果切除交叉互补修复酶1蛋白表达阳性率与患者的性别、年龄、吸烟状况、淋巴结转移情况、肿瘤组织学类型和临床分期均无明显相关性(P>0.05)。切除交叉互补修复酶1低表达者预后好,化疗有效率高,切除交叉互补修复酶1表达阴性和阳性的无病生存期分别为34.9个月和20.0个月(P=0.015),中位生存期分别为49.7个月和31.6个月;切除交叉互补修复酶1表达阴性的3年、5年生存率分别为58.4%、38.9%;切除交叉互补修复酶1表达阳性的3年、5年生存率分别为33.5%、18.3%(P=0.011)。结论以铂类为基础的化疗延长了非小细胞肺癌切除交叉互补修复酶1低表达患者的生存,术后可根据切除交叉互补修复酶1的表达水平决定是否选用含铂化疗。
Objective Platinum is the basis of chemotherapy for lung cancer, and the resection of cross-repair repair enzyme 1 expression level and platinum resistance and prognosis, the study analysis of resectable non-small cell lung cancer resection of cross-repair repair enzyme 1 expression and postoperative survival To explore their relationship with the prognosis of patients and with platinum resistance. Methods A total of 95 patients with stage Ⅱ ~ Ⅲ non-small cell lung cancer who were followed up from December 2005 to January 2009 were enrolled in this study. All patients underwent radical surgical resection and platinum-based chemotherapy. The immunohistochemical method was used to detect the excision of the surgically resected and repaired enzyme 1, and statistical analysis was performed. Results There was no significant correlation between the positive rate of cross-repair repair protein 1 and the gender, age, smoking status, lymph node metastasis, tumor histological type and clinical stage (P> 0.05). Patients with low expression of cross-repair repair enzyme 1 had a good prognosis and high chemotherapy efficiency. The negative and positive disease-free survival rates after resection of cross-repair repair enzyme 1 were 34.9 months and 20.0 months (P = 0.015), respectively The three-year and five-year survival rates of resection of cross-complementary repair enzyme 1 were 58.4% and 38.9%, respectively. The three-year and 5-year survival rate of resection of cross-complementary repair enzyme 1 Rates were 33.5% and 18.3%, respectively (P = 0.011). Conclusions Platinum-based chemotherapy prolongs the survival of patients with non-small cell lung cancer who have undergone resection of low-expression cross-repair repair enzyme 1, and whether or not platinum-based chemotherapy is selected depends on the expression level of cross-repair repair enzyme 1 after resection.